Reports Physician’s First Watch, about a study in the New England Journal of Medicine:
Sibutramine Increases Risk for MI and Stroke Among Patients with Heart Disease
The weight-loss drug sibutramine (Meridia) — up for review by FDA advisers on Sept. 15 — poses increased risk for cardiovascular events among adults with cardiovascular disease (CVD), according to a New England Journal of Medicine study.
Editorialists, however, take a stronger stance: “Given that sibutramine has minimal efficacy for weight loss, no apparent benefit for clinical outcomes, [and] a worrisome cardiovascular risk profile, … it is difficult to discern a credible rationale for keeping this medication on the market.”

Meridia = Sibutramine
http://nyti.ms/dzasvE
FDA advisory panel rejects another weight loss drug.